Voyager Therapeutics - Stock Price History | VYGR

Historical daily share price chart and data for Voyager Therapeutics since 2021 adjusted for splits. The latest closing stock price for Voyager Therapeutics as of September 24, 2021 is 2.94.
  • The all-time high Voyager Therapeutics stock closing price was 31.31 on March 06, 2018.
  • The Voyager Therapeutics 52-week high stock price is 12.65, which is 330.3% above the current share price.
  • The Voyager Therapeutics 52-week low stock price is 2.82, which is 4.1% below the current share price.
  • The average Voyager Therapeutics stock price for the last 52 weeks is 6.16.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Voyager Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 11.1098 13.5800 14.6600 6.8000 7.1500 -48.75%
2019 17.8972 9.4200 28.2900 8.0000 13.9500 48.40%
2018 18.3287 17.6300 31.3100 8.5900 9.4000 -43.37%
2017 12.6593 11.9700 25.8800 8.2400 16.6000 30.30%
2016 12.5015 21.1500 21.1500 8.5600 12.7400 -41.83%
2015 23.0354 17.7500 30.2000 17.5000 21.9000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.111B $0.171B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71